Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 8/20 | 0.73 |
| ▸ | CCND1 | P24385 | 8/20 | 0.73 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.67 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.66 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.66 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.66 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.66 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.64 |
| ▸ | CDK2 | P24941 | 4/20 | 0.64 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.64 |
| ▸ | MYLK | Q15746 | 4/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.55 |
| ▸ | PRKCG | P05129 | 3/20 | 0.55 |
| ▸ | PRKCB | P05771 | 3/20 | 0.55 |
| ▸ | PRKCA | P17252 | 3/20 | 0.55 |
| ▸ | PRKCH | P24723 | 3/20 | 0.55 |
| ▸ | PRKCI | P41743 | 3/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8122777 | 0.92 | PDGFRB (0.71) | CDK4CCND1ROCK2PDGFRBCAMK2B | |
| SCHEMBL8121576 | 0.85 | CDK4 (1.00) | CDK4CCND1ROCK2CAMK2BCAMK2G | |
| SCHEMBL8128623 | 0.83 | ROCK2 (1.00) | CDK4CCND1ROCK2PDGFRBCAMK2B | |
| SCHEMBL8125099 | 0.81 | PDGFRB (0.54) | CDK4CCND1ROCK2PDGFRBCCNE1 | |
| Gw296115X SCHEMBL8120713 | 0.81 | PDGFRB (1.00) | CDK4CCND1ROCK2PDGFRBCAMK2B | |
| Gw296115X SCHEMBL31281911 | 0.81 | PDGFRB (1.00) | CDK4CCND1ROCK2PDGFRBCAMK2B | |
| SCHEMBL14440449 | 0.80 | ROCK2 (0.56) | CDK4CCND1ROCK2PDGFRBCAMK2B | |
| SCHEMBL14440448 | 0.80 | ROCK2 (0.56) | CDK4CCND1ROCK2PDGFRBCAMK2B | |
| SCHEMBL8355911 | 0.80 | ROCK2 (0.56) | CDK4CCND1ROCK2PDGFRBCAMK2B | |
| SCHEMBL8353847 | 0.80 | ROCK2 (0.56) | CDK4CCND1ROCK2PDGFRBCAMK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009511-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2008-01-10 | — | — | US | claimed |
| US-20060009492-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2006-01-12 | — | — | US | claimed |
| EP-0642513-B1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | KTB TUMORFORSCHUNGSGESELLSCHAF (DE) | 2000-08-09 | — | — | EP | claimed |
| US-5883114-A | TREATING CANCEROUS TUMORS, INFLAMMATORY DISEASES, AND ALLERGIES | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-03-16 | — | — | US | claimed |
| EP-0642513-A1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1995-03-15 | — | — | EP | claimed |
| WO-1993024491-A1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | Gödecke Aktiengesellschaft (DE) | 1993-12-09 | — | — | WO | claimed |
| US-20080009511-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2008-01-10 | — | — | US | disclosed |
| US-20060009492-A1 | Cancer treatment with compounds inhibiting PKC alpha | LU ZHIMIN | 2006-01-12 | — | — | US | disclosed |
| EP-0642513-B1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | KTB TUMORFORSCHUNGSGESELLSCHAF (DE) | 2000-08-09 | — | — | EP | disclosed |
| US-5945440-A | Indolocarbazole imides and the use thereof | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-08-31 | — | — | US | disclosed |
| US-5883114-A | TREATING CANCEROUS TUMORS, INFLAMMATORY DISEASES, AND ALLERGIES | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-03-16 | — | — | US | disclosed |
| EP-0642513-A1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993024491-A1 | INDOLOCARBAZOLE IMIDES AND THEIR USE | Gödecke Aktiengesellschaft (DE) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009511-A1 | Cancer treatment with compounds inhibiting PKC alpha | PRKCE, ROCK1, PRKCA | CDK4 1621/4885CCND1 2051/4885ROCK2 16/4885 |
| US-20060009492-A1 | Cancer treatment with compounds inhibiting PKC alpha | PRKCE, ROCK1, PRKCA | CDK4 1621/4885CCND1 2051/4885ROCK2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.